Intensity Therapeutics' INT230-6 shows potential in metastatic sarcoma survival 07:08 INTS Intensity Therapeutics announced that data from its open-label phase 1/2 study of novel lead asset, INT230-6, as a monotherapy or in combination with ipilimumab in adult subjects with metastatic sarcomas, will be presented at the Connective Tissue Oncology Society Annual Meeting in Vancouver. Dosing with INT230-6 resulted in a median overall survival of 715 days vs. 205 days on historical sarcoma control. "Preliminary data suggests that INT230-6, as a monotherapy or in combination with the immune checkpoint blocker ipilimumab, demonstrates direct tumor killing in soft tissue sarcoma (STS) and elicits an anti-cancer immune response within the injected tumor," stated principal investigator Matthew Ingham. "To date, INT230-6 treatment related adverse events are mostly low grade and the drug is well-tolerated either as a monotherapy or in combination with ipilimumab. Additionally, in patients who had 40% or more of their tumor burden treated with INT230-6, an exploratory analysis showed that overall survival was improved when compared to historical benchmarks for this patient population." CEO Lewis Bender added, "The compelling safety and efficacy results from use of our drug in treating such a deadly and hard-to-treat cancer as soft tissue sarcomas underscore the potential of this treatment. The promising data supports our belief that INT230-6 could show clinical benefit with lower levels of off-target side effects compared to standard chemotherapies. We have designed a randomized phase 3 trial protocol to evaluate INT230-6 versus standard of care in patients with advanced soft tissue sarcomas and look forward to initiation of the study."
TED! I'm sorry I owe you one. Foot Locker jumps 17% to $38.80 after Q3 results beat, FY22 guidance raised
FL--->+17% ★★★★★★★★★★★★★★ HE DID IT AGAIN!!! ★★★★★★★★★★★★★ #1 FOR A REASON _________________________________________ STONEY!!!! DON'T YOU REGRET TELLING EVERYONE TO GET OUT AT 3750 ON THE S&P?
Unclear if this is an upcoming IPO? Intensity Therapeutics sets more terms for proposed $10M IPO Sep. 21, 2022 4:12 PM ET Intensity Therapeutics, Inc. (INTS)
what did I miss? I do read everything sometimes I do it on the weekend and go back // I don't do it every day What Did I miss????? TrueCar?
Foot Locker stock runs nearly 20% higher on raised full-year forecasts Nov. 18, 2022 7:11 AM ETFoot Locker, Inc. (FL) Dig the ugly socks! that's my style. High & Ugly.
Dude... quit letting Trump live rent free in your head. Move on. He had some good policies. Maybe he had some bad ones... so what. But your brain is too binary. You lack critical thought. That's not good Stoney.